Ligand Pharmaceuticals Incorporated

8-K Entered a material agreement; Completed an acquisition or disposition; Took on a direct financial obligation; Regulation FD disclosure Jul 14, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Other events Jun 25, 2026 8-K Entered a material agreement; Other events Jun 22, 2026 8-K Director or officer change; Shareholder vote results Jun 9, 2026 8-K Entered a material agreement May 18, 2026 10-Q Quarter ended 2026-03-31 May 8, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Terminated a material agreement Apr 30, 2026 8-K Entered a material agreement; Other events Apr 27, 2026 10-K Fiscal year ended 2025-12-31 Feb 27, 2026 8-K Results of operations (earnings release) Feb 26, 2026 8-K Regulation FD disclosure Dec 18, 2025 10-Q Quarter ended 2025-09-30 Nov 7, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Entered a material agreement; Took on a direct financial obligation Sep 16, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Other events Aug 14, 2025 8-K Entered a material agreement; Other events Aug 11, 2025 10-Q Quarter ended 2025-06-30 Aug 8, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Regulation FD disclosure Jul 2, 2025 8-K Shareholder vote results Jun 9, 2025 10-Q Quarter ended 2025-03-31 May 9, 2025 8-K Results of operations (earnings release) May 8, 2025 8-K Regulation FD disclosure Apr 17, 2025 10-K Fiscal year ended 2024-12-31 Feb 28, 2025 8-K Results of operations (earnings release) Feb 27, 2025 8-K Entered a material agreement; Regulation FD disclosure Feb 25, 2025 10-Q Quarter ended 2024-09-30 Nov 8, 2024 8-K Results of operations (earnings release) Nov 7, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Results of operations (earnings release) Aug 6, 2024 8-K Director or officer change Aug 2, 2024 8-K Completed an acquisition or disposition Jul 17, 2024 8-K Entered a material agreement; Took on a direct financial obligation Jul 10, 2024 8-K Entered a material agreement; Regulation FD disclosure Jul 8, 2024 8-K Other events Jun 27, 2024 8-K Other events Jun 18, 2024 8-K Director or officer change; Shareholder vote results Jun 17, 2024 8-K Other events May 30, 2024 10-Q Quarter ended 2024-03-31 May 8, 2024